Wugen, Inc.: Wugen Presents New Preclinical Data Demonstrating Enhanced Anti-Tumor Activity of WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress

-- WU-NK-101 exhibited enhanced metabolic flexibility and resistance to tumor microenvironment (TME) immunosuppression relative to conventional natural killer (NK) cells -- -- WU-NK-101 demonstrated

Related Keywords

Vienna ,Wien ,Austria ,Kostenloser Wertpapierhandel ,Dan Kemp ,Jan Davidson Moncada ,Elsie Yau ,Stern Investor Relations Inc ,Wugen Inc ,European Hematology Association ,Chief Executive Officer ,Acute Myeloid Leukemia ,Chief Medical Officer ,Stern Investor Relations ,Wugen ,Presents ,Reclinical ,Data ,Emonstrating ,Nhanced ,Anti ,Humor ,Activity ,European ,Hematology ,Association ,022 ,Hybrid ,Congress ,